Prostate cancer of high oncological risk. Current trends in diagnosis and surgical treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A group of patients with high risk prostate cancer was identified in the late 1990s. Since then, management of this group of patients has undergone some serious changes. The article provides a brief overview of the most significant changes, primarily in surgical treatment, over the past 3 years. Besides, the authors present their views on perspective treatments and possible changes in the near future.

Full Text

Restricted Access

About the authors

E. A Bezrukov

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: eabezrukov@rambler.ru
Dr.Med.Sci., Prof. at the Department of Urology

L. M Rapoport

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University); Research Institute for Uronephrology and Human Reproductive Health

Email: leonidrapoport@yandex.ru
Dr.Med.Sci., Professor at the Department of Urology; Deputy Director for Clinical Care

E. V Shpot’

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: shpot@inbox.ru
Ph.D., Associate Professor at the Department of Urology

M. E Enikeev

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: enikmic@mail.ru
Dr.Med.Sci., Head of the 2nd Department of the Urology Clinic, Professor at the Department of Urology

A. O Morozov

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Urologist, Ph.D. Student at the Department of Urology

References

  1. Papsidero L.D., Wang M.C., Valenzuela L.A., Murphy G.P., Chu T.M. A prostate antigen in sera of prostatic cancer patients. Cancer Res. 1980;40(7):2428-2432.
  2. D’Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., Tomaszewski J.E., Renshaw A.A., Kaplan I., Beard C.J. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998;280(11):969-974.
  3. Harty N.J., Kozinn S.I., Canes D., Sorcini A., Moinzadeh A. Comparison of positive surgical margin rates in high risk prostate cancer: open versus minimally invasive radical prostatectomy. Int Braz J. Urol. 2013;39(5):639-646; discussion 647-638.
  4. Perez B.A., Koontz B.F. Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer. Urol Oncol. 2015;33(5):226-234.
  5. Nomiya T., Tsuji H., Toyama S., Maruyama K., Nemoto K., Tsujii H., Kamada T. Management of high-risk prostate cancer: radiation therapy and hormonal therapy. Cancer Treat Rev. 2013;39(8): 872-878.
  6. Spencer J.A., Chng W.J., Hudson E., Boon A.P., Whelan P. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. Br J. Radiol. 1998;71(851):1130-1135.
  7. Pasoglou V., Larbi A., Collette L., Annet L., Jamar F., Machiels J.P., Michoux N., Vande Berg B.C., Tombal B., Lecouvet F.E. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified «all-in-one» imaging approach? The Prostate. 2014;74(5):469-477.
  8. Raskolnikov D., George A.K., Rais-Bahrami S., Turkbey B., Siddiqui M.M., Shakir N.A., Okoro C., Rothwax J.T., Walton-Diaz A., Sankineni S., Su D., Stamatakis L., Merino M.J., Choyke P.L., Wood B.J., Pinto P.A. The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying Men for Risk of Extracapsular Extension at Radical Prostatectomy. J. Urol. 2015;194(1):105-111.
  9. Котов С.В., Перов Р.А., Мартьянова Н.А., Беломытцев С.В., Юсуфов А.Г., Трынов Р.В., Суренков Д.Н., Страт А.А., Сулейманов М.С., Арбузов И.А. Радикальная простатэктомии у пациентов группы высокого и очень высокого риска рака предстательной железы. XIV Конгресс Российского общества урологов. Саратов. 2014; 167-168
  10. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU international. 2005;95(6):751-756.
  11. Soylu F.N., Peng Y., Jiang Y., Wang S., Schmid-Tannwald C., Sethi I., Eggener S., Antic T., Oto A. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology. 2013;267(3):797-806.
  12. Mearini L., Zucchi A., Costantini E., Bini V., Nunzi E., Porena M. Outcomes of radical prostatectomy in clinically locally advanced N0M0 prostate cancer. Urol Int. 2010;85(2):166-172.
  13. Abern M.R., Terris M.K., Aronson W.J., Kane C.J., Amling C.L., Cooperberg M.R., Freedland S.J. The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically highrisk prostate cancer. Cancer. 2014;120(11):1656-1662.
  14. Joniau S., Tosco L., Briganti A., Vanden Broeck T., Gontero P., Karnes R.J., Spahn M., Van Poppel H.; European Multicenter Prostate Cancer Clinical and Translational research group. Results of surgery for high-risk prostate cancer. Curr Opin Urol. 2013;23(4):342-348.
  15. Retel V.P., Bouchardy C., Usel M., Neyroud-Caspar I., Schmidlin F., Wirth G., Iselin C., Miralbell R., Rapiti E. Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study. BMC Urol. 2014;14:86.
  16. Shikanov S., Marchetti P., Desai V., Razmaria A., Antic T., Al-Ahmadie H., Zagaja G., Eggener S., Brendler C., Shalhav A. Short (
  17. Izard J.P., True L.D., May P., Ellis W.J., Lange P.H., Dalkin B., Lin D.W., Schmidt R.A., Wright J.L. Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence. Am J. Surg Pathol. 2014;38(3):333-338.
  18. Stewart S.B., Boorjian S.A. Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urol Oncol. 2015;33(5):235-244.
  19. Heidenreich A., Pfister D., Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J. Urol. 2015;193(3):832-838.
  20. Mitchell C.R., Boorjian S.A., Umbreit E.C., Rangel L.J., Carlson R.E., Karnes R.J. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012;110(11): 1709-1713.
  21. Boorjian S.A., Karnes R.J., Viterbo R., Rangel L.J., Bergstralh E.J., Horwitz E.M., Blute M.L., Buyyounouski M.K. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13): 2883-2891.
  22. Inman B.A., Davies J.D., Rangel L.J., Bergstralh E.J., Kwon E.D., Blute M.L., Karnes R.J., Leibovich B.C. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer. 2008;113(7):1544-1551.
  23. Moltzahn F., Karnes J., Gontero P., Kneitz B., Tombal B., Bader P., Briganti A., Montorsi F., Van Poppel H., Joniau S. et al. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. Prostate Cancer Prostatic Dis. 2015;18(1):31-37.
  24. Schroder F.H., Kurth K.H., Fossa S.D., Hoekstra W., Karthaus P.P., De Prijck L., Collette L. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol. 2009;55(1):14-22.
  25. Engel J., Bastian P.J., Baur H., Beer V., Chaussy C., Gschwend J.E., Oberneder R., Rothenberger K.H., Stief C.G., Holzel D. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010;57(5):754-761.
  26. Tilki D., Mandel P., Seeliger F., Kretschmer A., Karl A., Ergun S., Seitz M., Stief C.G. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J. Urol. 2015;193(2):484-490.
  27. Joniau S., Van den Bergh L., Lerut E., Deroose C.M., Haustermans K., Oyen R., Budiharto T., Ameye F., Bogaerts K., Van Poppel H. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol. 2013;63(3):450-458.
  28. Jeschke S., Lusuardi L., Myatt A., Hruby S., Pirich C., Janetschek G. Visualisation of the lymph node pathway in real time by laparoscopic radioisotope- and fluorescence-guided sentinel lymph node dissection in prostate cancer staging. Urology. 2012;80(5): 1080-1086.
  29. Satkunasivam R., Kim A.E., Desai M., Nguyen M.M., Quinn D.I., Ballas L., Lewinger J.P., Stern M.C., Hamilton A.S., Aron M., Gill I.S. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J. Urol. 2015;194(2):378-385.
  30. Abdollah F., Sood A., Sammon J.D., Hsu L., Beyer B., Moschini M., Gandaglia G., Rogers C.G., Haese A., Montorsi F., Graefen M., Briganti A., Menon M. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. Eur Urol. 2015;68(3):497-505.
  31. Pilecki M.A., McGuire B.B., Jain U., Kim J.Y., Nadler R.B. National multi-institutional comparison of 30-day postoperative complication and readmission rates between open retropubic radical prostatectomy and robot-assisted laparoscopic prostatectomy using NSQIP. J. Endourol. 2014;28(4):430-436.
  32. Kumar A., Samavedi S., Bates A.S., Mouraviev V., Coelho R.F., Rocco B., Patel V.R. Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy. J. Robot Surg. 2017;11(2):129-138.
  33. Vasdev N., Agarwal S., Rai B.P., Soosainathan A., Shaw G., Chang S., Prasad V., Mohan S.G., Adshead J.M. Intraoperative Frozen Section of the Prostate Reduces the Risk of Positive Margin Whilst Ensuring Nerve Sparing in Patients with Intermediate and High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy: First Reported UK Series. Curr Urol. 2016;9(2):93-103.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies